Dextran-maleic acid monoesters and hydrogels based thereon
    2.
    发明授权
    Dextran-maleic acid monoesters and hydrogels based thereon 有权
    基于其的葡聚糖 - 马来酸单酯和水凝胶

    公开(公告)号:US06476204B1

    公开(公告)日:2002-11-05

    申请号:US09743790

    申请日:2001-01-19

    IPC分类号: C07H1510

    摘要: Biodegradable hydrogels are formed by photocrosslinking dextran-maleic acid monoesters in which the average degree of substitution of each glucose unit of each &agr;-D-glucopyranosyl of dextran by maleic acid ranges from 0.60 to 1.6 and which have a weight average molecular weight ranging from 40,000 to 80,000 on a dextran basis. The hydrogels at pH 7 have maximum swelling ratios ranging from 500 to 1,500 percent. The hydrogels are characterized by increase in swelling ratio as average degree of substitution increases. The hydrogels are useful, for example, for drug delivery and solubility enhancers of drugs, as protective encapsulators of viruses used in gene therapy, and for conventional uses of hydrogels.

    摘要翻译: 通过光学交联葡聚糖 - 马来酸单酯形成可生物降解的水凝胶,其中马来酸对葡聚糖的每个α-D-吡喃葡萄糖基的每个葡萄糖单元的平均取代度为0.60-1.6,重均分子量为40,000 以葡聚糖为基准,达到80,000。 pH7的水凝胶具有最大的膨胀比范围为500至1,500%。 水凝胶的特征在于平均取代度增加溶胀比增加。 水凝胶可用于例如药物递送和药物溶解度增强剂,作为用于基因治疗的病毒的保护性封装剂和用于水凝胶的常规用途。

    Controlled release of doxorubicin
    3.
    发明授权
    Controlled release of doxorubicin 失效
    多柔比星的控制释放

    公开(公告)号:US06369037B1

    公开(公告)日:2002-04-09

    申请号:US09677859

    申请日:2000-10-03

    IPC分类号: A61K3170

    CPC分类号: A61K9/0024 A61K47/36

    摘要: A controlled release doxorubicin containing composition comprises doxorubicin physically entrapped in a dextran-methacrylate biodegradable hydrogel. The composition provides a rapid initial release of doxorubicin over a period of 5 to 7 hours followed by slow release. Increased degree of substitution in the dextran methacrylate decreases cumulative doxorubicin release. The composition provides higher cumulative release in acid pH (e.g., the stomach) than at physiological pH at lower degrees of substitution. The composition allows administration alternatives to the bolus intravenous and continuous intravenous methods of administration now used for doxorubicin. The composition can be prepared without the use of heat (which can result in heat destruction of doxorubicin) and is prepared without chemical cross-linker such as glutaraldehyde and the toxicity associated therewith.

    摘要翻译: 含有控释的多柔比星含有组合物包括物质包埋在葡聚糖 - 甲基丙烯酸甲酯可生物降解的水凝胶中的多柔比星。 该组合物在5至7小时期间提供阿霉素的快速初始释放,随后缓慢释放。 甲基葡聚糖甲基丙烯酸酯中的增加的取代度降低了多柔比星的释放。 组合物在酸性pH(例如胃)中提供比在较低取代度下在生理pH下更高的累积释放。 该组合物允许给予药物替代用于多柔比星的静脉内和连续静脉注射方法。 可以在不使用热的情况下制备组合物(其可导致多柔比星的热破坏),并且在没有化学交联剂如戊二醛和与其相关的毒性的情况下制备。